MELBOURNE Australia 9 February 2018: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company will host a meeting of investigators involved in the current clinical trial of its HER-Vaxx (IMU 131) cancer vaccine on Sunday 11 February 2018 in Bangkok Thailand.
The meeting brings together investigators from all trial sites in Hong Kong, Thailand and Taiwan to share and discuss their experience recruiting and results of treating the unmet medical needs of patients with metastatic gastric cancer and review early data from the current Phase 1b trial of the HER-Vaxx cancer therapy.
The current trial seeks to confirm tolerability and safety of the treatment as well as identify optimal dosing in combination with chemotherapy to prolong survival in patients with metastatic gastric cancer.
For further information please download PDF attached:
Download this document
